ECSP056090A - Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar - Google Patents

Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar

Info

Publication number
ECSP056090A
ECSP056090A EC2005006090A ECSP056090A ECSP056090A EC SP056090 A ECSP056090 A EC SP056090A EC 2005006090 A EC2005006090 A EC 2005006090A EC SP056090 A ECSP056090 A EC SP056090A EC SP056090 A ECSP056090 A EC SP056090A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
sugar
solid pharmaceutical
spirit
composition including
Prior art date
Application number
EC2005006090A
Other languages
English (en)
Spanish (es)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of ECSP056090A publication Critical patent/ECSP056090A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EC2005006090A 2003-04-08 2005-10-07 Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar ECSP056090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
ECSP056090A true ECSP056090A (es) 2006-03-01

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006090A ECSP056090A (es) 2003-04-08 2005-10-07 Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar

Country Status (41)

Country Link
US (11) US20060275357A1 (show.php)
EP (5) EP2319502A1 (show.php)
JP (3) JP5495467B2 (show.php)
KR (3) KR20050121712A (show.php)
CN (2) CN101797241B (show.php)
AR (3) AR043987A1 (show.php)
AT (3) ATE414508T1 (show.php)
AU (1) AU2004228929B2 (show.php)
BE (2) BE1015972A5 (show.php)
BR (1) BRPI0409250B8 (show.php)
CA (2) CA2707750A1 (show.php)
CL (2) CL2004000745A1 (show.php)
CY (3) CY1110260T1 (show.php)
DE (4) DE102004016947A1 (show.php)
DK (2) DK1613288T3 (show.php)
EC (1) ECSP056090A (show.php)
ES (3) ES2556947T3 (show.php)
FR (2) FR2854073B1 (show.php)
GB (1) GB2400318B (show.php)
GR (1) GR1005052B (show.php)
HR (3) HRP20100600A2 (show.php)
HU (2) HUE028247T2 (show.php)
IL (3) IL170888A (show.php)
IS (2) IS2682B (show.php)
IT (1) ITMI20040682A1 (show.php)
LU (1) LU91867I2 (show.php)
MA (1) MA27729A1 (show.php)
MX (1) MXPA05010860A (show.php)
MY (1) MY141249A (show.php)
NO (4) NO329332B1 (show.php)
NZ (3) NZ586280A (show.php)
PE (5) PE20050396A1 (show.php)
PL (2) PL1613288T3 (show.php)
PT (1) PT1613288E (show.php)
RU (5) RU2358716C2 (show.php)
SG (1) SG175449A1 (show.php)
SI (2) SI2316431T1 (show.php)
TN (1) TNSN05256A1 (show.php)
TW (1) TWI332847B (show.php)
WO (1) WO2004089341A1 (show.php)
ZA (1) ZA200507394B (show.php)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101174930B1 (ko) * 2004-07-30 2012-08-17 노파르티스 아게 ２-아미노-１,３-프로판디올 화합물의 화합물 제제
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
DK1926483T3 (da) * 2005-09-09 2011-03-14 Novartis Ag Behandling af autoimmune sygdomme
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
UA101303C2 (uk) 2006-06-19 2013-03-25 Протеолікс, Інк. Сполуки для інгібування ферменту протеасоми
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
LT3103448T (lt) * 2006-09-26 2019-10-10 Novartis Ag Farmacinės kompozicijos, apimančios s1p moduliatorių
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
CN101652139A (zh) * 2007-03-29 2010-02-17 第一三共株式会社 药物组合物
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
AU2009227629B2 (en) 2008-03-17 2014-09-04 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
WO2009152922A1 (de) * 2008-06-20 2009-12-23 Merck Patent Gmbh Direkt verpressbare und schnell zerfallende tablettenmatirx
SI2334202T1 (sl) * 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
MX2011004962A (es) * 2008-11-11 2011-05-30 Novartis Ag Formas cristalinas de hcl de fingolimod.
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
CA2804262C (en) 2010-07-02 2016-04-05 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
CA2825014C (en) 2011-01-19 2019-01-08 John Mckearn Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014205529B2 (en) 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
MX2023008907A (es) * 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
SK282225B6 (sk) 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP0990440B1 (en) * 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
EP1319651B1 (en) * 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物

Also Published As

Publication number Publication date
DE102004016947A1 (de) 2004-10-21
CN101797241A (zh) 2010-08-11
EP1613288B1 (en) 2008-11-19
PE20050396A1 (es) 2005-07-05
IL170888A (en) 2010-06-16
GB0407819D0 (en) 2004-05-12
HRP20100601B1 (hr) 2016-12-02
US8324283B2 (en) 2012-12-04
KR20110005320A (ko) 2011-01-17
US20080311188A1 (en) 2008-12-18
RU2010147000A (ru) 2012-08-10
GB2400318A (en) 2004-10-13
NZ542622A (en) 2009-01-31
JP2004307506A (ja) 2004-11-04
AR078781A2 (es) 2011-11-30
DE122011100047I1 (de) 2011-12-15
GR20040100121A (el) 2004-12-17
AR043987A1 (es) 2005-08-17
IS8114A (is) 2005-11-01
IL197578A (en) 2015-10-29
ZA200507394B (en) 2007-03-28
CA2521325A1 (en) 2004-10-21
IL242037A0 (en) 2015-11-30
ATE414508T1 (de) 2008-12-15
BRPI0409250A (pt) 2006-03-28
HRP20050886B1 (en) 2011-01-31
HUE028247T2 (en) 2016-12-28
BRPI0409250B1 (pt) 2017-07-11
AT501681A1 (de) 2006-10-15
US20140011885A1 (en) 2014-01-09
FR2854073A1 (fr) 2004-10-29
EP2769713A1 (en) 2014-08-27
KR20050121712A (ko) 2005-12-27
US20130108675A1 (en) 2013-05-02
US20110105620A1 (en) 2011-05-05
PE20150676A1 (es) 2015-05-17
PE20090743A1 (es) 2009-07-17
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
TWI332847B (en) 2010-11-11
US20090203798A1 (en) 2009-08-13
JP2011006461A (ja) 2011-01-13
KR20120101148A (ko) 2012-09-12
AU2004228929B2 (en) 2008-02-07
IS8885A (is) 2010-02-25
HRP20100600A2 (hr) 2011-03-31
ES2228282B1 (es) 2006-02-16
CA2707750A1 (en) 2004-10-21
HK1155647A1 (en) 2012-05-25
RU2475236C2 (ru) 2013-02-20
DE202004021680U1 (de) 2010-04-22
JP2013177404A (ja) 2013-09-09
EP2008650A2 (en) 2008-12-31
EP2008650A3 (en) 2011-04-27
US20140255497A1 (en) 2014-09-11
NO334116B1 (no) 2013-12-16
MXPA05010860A (es) 2006-05-25
NO20100250L (no) 2006-01-09
KR101367574B1 (ko) 2014-02-25
RU2005134173A (ru) 2006-09-10
TNSN05256A1 (en) 2007-07-10
NO20055231D0 (no) 2005-11-07
HUS1100016I1 (hu) 2016-08-29
PE20130200A1 (es) 2013-03-09
NO329332B1 (no) 2010-09-27
BE2011C030I2 (show.php) 2023-03-07
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
CA2521325C (en) 2010-09-14
NZ586280A (en) 2011-12-22
HRP20050886A2 (en) 2006-11-30
MY141249A (en) 2010-03-31
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
AU2004228929A1 (en) 2004-10-21
DK1613288T3 (da) 2009-03-23
US20190175527A1 (en) 2019-06-13
SG175449A1 (en) 2011-11-28
PE20131352A1 (es) 2013-11-14
DK2316431T3 (en) 2016-01-11
SI2316431T1 (sl) 2016-04-29
EP2316431B1 (en) 2015-09-30
US20170290787A1 (en) 2017-10-12
HK1091114A1 (en) 2007-01-12
EP2319502A1 (en) 2011-05-11
ES2228282A1 (es) 2005-04-01
WO2004089341A1 (en) 2004-10-21
GR1005052B (el) 2005-11-30
CY1117071T1 (el) 2017-04-05
CY2011013I2 (el) 2014-04-09
ITMI20040682A1 (it) 2004-07-06
US20220031609A1 (en) 2022-02-03
RU2012148593A (ru) 2014-05-20
LU91867I9 (show.php) 2019-01-03
BRPI0409250B8 (pt) 2022-01-18
IS2682B (is) 2010-10-15
NO20131287L (no) 2006-01-09
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
JP5543298B2 (ja) 2014-07-09
RU2475237C2 (ru) 2013-02-20
RU2010146697A (ru) 2012-05-27
RU2009105403A (ru) 2010-08-27
CN1767819B (zh) 2010-07-28
HRP20100601A2 (hr) 2011-03-31
CL2004000745A1 (es) 2005-02-11
NO2011016I1 (no) 2011-09-19
PT1613288E (pt) 2009-02-25
AR078782A2 (es) 2011-11-30
CN1767819A (zh) 2006-05-03
NO335120B1 (no) 2014-09-22
MA27729A1 (fr) 2006-01-02
PL1613288T3 (pl) 2009-07-31
EP1613288A1 (en) 2006-01-11
GB2400318B (en) 2005-08-10
US20200237690A1 (en) 2020-07-30
DE602004017847D1 (de) 2009-01-02
NO2011016I2 (no) 2012-08-27
LU91867I2 (fr) 2011-11-08
FR11C0036I1 (fr) 2011-10-14
ES2556947T3 (es) 2016-01-21
FR11C0036I2 (fr) 2023-12-29
RU2358716C2 (ru) 2009-06-20
NZ592339A (en) 2012-09-28
AT501681B1 (de) 2012-04-15
JP5495467B2 (ja) 2014-05-21
US20060275357A1 (en) 2006-12-07
CY1110260T1 (el) 2014-04-09
TW200503784A (en) 2005-02-01
SI1613288T1 (sl) 2009-04-30
FR2854073B1 (fr) 2008-03-14
AT504853A2 (de) 2008-08-15
CY2011013I1 (el) 2014-04-09
IE20040246A1 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
ECSP056090A (es) Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar
AR067347A1 (es) Combinacion antihelmintica
MX2009010289A (es) Composiciones para administracion nasal.
CO6480977A2 (es) Agonistas de gpr119
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
HN2006007884A (es) Derivados de oxiindol
AR059357A1 (es) Formulaciones farmaceuticas
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
UY30065A1 (es) Composiciones farmacéuticas para la erradicación de helicobacter pylori
MY142039A (en) New association between a heterocyclic compound and an antioxidant agent, and pharmaceutical compositions containing them
ECSP972162A (es) Formas solidas de dosificacion oral que contienen valsartan
ECSP055749A (es) Formulacion de tramadol de liberacion sostenida con eficacia de 24 horas
CL2008001541A1 (es) Composicion farmaceutica solida para administracion oral que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p) y un alcohol de azucar (div. sol. 745-04).
ECSP045461A (es) Unidades de dosificación progestagénica
CL2008003633A1 (es) Uso de una matriz fisica que comprende un eter de celulosa para la manufactura de una formulacion que proporciona una liberacion controlada de una sal de oxicodona, util en el tratamiento del dolor.
UA68667C2 (uk) Лікарський препарат протидіабетичної дії на основі гліклазиду
ECSP003313A (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico